Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02860000
Recruitment Status : Recruiting
First Posted : August 9, 2016
Last Update Posted : April 18, 2019
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Mayo Clinic

Brief Summary:
This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer.

Condition or disease Intervention/treatment Phase
Estrogen Receptor Status HER2/Neu Negative Invasive Breast Carcinoma Postmenopausal Stage III Breast Cancer Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Breast Cancer Drug: Alisertib Drug: Fulvestrant Other: Laboratory Biomarker Analysis Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. To assess the impact on objective tumor response rate (using Response Evaluation Criteria in Solid Tumors [RECIST] criteria) with the addition of fulvestrant to alisertib in women with endocrine resistant, advanced estrogen receptor positive breast cancer.

SECONDARY OBJECTIVES:

I. To evaluate the safety profile of each treatment regimen. II. To assess the impact on median progression-free survival with the addition of fulvestrant to alisertib.

III. To obtain estimated tumor response rate and the median progression-free survival time during alisertib and fulvestrant treatment in the cohort of patients who progress during alisertib monotherapy, and crossover to receive the combination of alisertib and fulvestrant.

TERTIARY OBJECTIVES:

I. To assess the changes in aurora A kinase, SMAD5 and SOX2 expression and phosphorylation in tumor tissue after first cycle of assigned treatment.

II. To assess the changes in estrogen receptor (ER) expression and function in tumor tissue after the first cycle of assigned treatment.

III. To generate patient derived xenografts (PDX) from tumors collected at baseline and progression of disease (PD) in order to identify mechanisms associated with both de novo and acquired alisertib resistance.

IV. After the first cycle of treatment, to assess changes in aurora A kinase, phosphorylated (p)~SOX2 and ER expression on circulating tumor cells (CTCs), and to assess concordance between change in expression with tumor tissue and CTCs.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive alisertib orally (PO) twice daily (BID) on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.

ARM II: Patients receive fulvestrant intramuscularly (IM) over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Actual Study Start Date : July 6, 2017
Estimated Primary Completion Date : December 15, 2021
Estimated Study Completion Date : December 15, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Fulvestrant

Arm Intervention/treatment
Experimental: Arm I (alisertib)
Patients receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression, may cross-over to Arm II.
Drug: Alisertib
Given PO
Other Names:
  • Aurora A Kinase Inhibitor MLN8237
  • MLN-8237
  • MLN8237

Other: Laboratory Biomarker Analysis
Correlative studies

Experimental: Arm II (alisertib, fulvestrant)
Patients receive fulvestrant IM over 1-2 minutes on days 1 and 15 of course 1 and on day 1 of all subsequent courses. Patients also receive alisertib PO BID on days 1-3, 8-10, and 15-17. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drug: Alisertib
Given PO
Other Names:
  • Aurora A Kinase Inhibitor MLN8237
  • MLN-8237
  • MLN8237

Drug: Fulvestrant
Given IM
Other Names:
  • Faslodex
  • Faslodex(ICI 182,780)
  • ICI 182,780
  • ICI 182780
  • ZD9238

Other: Laboratory Biomarker Analysis
Correlative studies




Primary Outcome Measures :
  1. Tumor response rate defined as 100% times the number of patients who meet the criteria for complete response (CR) or partial response (PR) using RECIST criteria version 1.1 [ Time Frame: Up to 5 years ]
    For arm I, tumor response rate is defined as 100% times the number of patients who meet the criteria for CR or PR on 2 consecutive evaluations approximately 8 weeks apart during treatment with alisertib monotherapy divided by the number of patients who started alisertib monotherapy. For arm II, tumor response rate is defined as 100% times the number of patients who meet the criteria for CR or PR on 2 consecutive evaluations approximately 8 weeks apart during treatment with combination of alisertib and fulvestrant divided by the number of patients who started treatment with the combination of a


Secondary Outcome Measures :
  1. Biomarkers and ER alpha expression assessed using tumor tissue [ Time Frame: Up to 4 weeks ]
    Spearman rank correlation coefficient will be used to examine the association between ER alpha expression and the biomarkers: CD44, CD24, total and phosphorylated expression of AURKA, SMAD5, and SOX2. A two sample test of the difference in proportions will be used to examine whether weak or no phosphorylated expression of AURKA, SMAD5, and SOX2 after one cycle of alisertib is associated with clinical benefit (CR + PR + stable disease on treatment for at least 6 months).

  2. Change in blood biomarker levels [ Time Frame: Baseline to 28 days ]
    Percent change in CTC expression of aurora A kinase, ER, and phospho- SOX2 expression from pre-treatment levels will be determined for each patient. Bland-Altman plots and weighted kappa statistics will be used to examine the concordance between the percent change in aurora A kinase, ER, and phospho-SOX2 expression from pre-treatment levels in CTC and in tumor tissue.

  3. Change in tumor biomarker levels [ Time Frame: Baseline to 28 days ]
    Spearman rank correlation coefficient will be used to examine the association of maximum percentage of tumor shrinkage during treatment with the percent change after 1 cycle of treatment in aurora A Kinase (AAK) expressing cells, as well as percent changes after 1 cycle of treatment in tissue ER alpha, SMAD5, SOX2 expression and phosphorylation.

  4. Clinical benefit rate (CBR) during initial treatment defined as proportion of patients who completed 6 courses of treatment without documentation of disease progression [ Time Frame: At 24 weeks ]
    For initial treatment in each arm, the CBR at 24 weeks will be defined as the proportion of patients who completed 6 cycles of treatment without documentation of disease progression. A 90% confidence interval for the CBR will be constructed using the Duffy-Santner approach to take into account the sequential nature of the study design.

  5. Duration of response defined as time from randomization to disease progression among those patients whose disease meets the RECIST criteria for CR or PR on 2 consecutive evaluations approximately 8 weeks apart during initial treatment [ Time Frame: Up to 5 years ]
    Will be estimated using the Kaplan-Meier method.

  6. Incidence of adverse events graded by Common Terminology Criteria-Criteria for Adverse Events (CTCAE) version 4.0 [ Time Frame: Up to 30 days after last administration of study drug ]
    The CTCAE version 4.0 will be used to grade and assign attribution to each adverse event reported during initial treatment and crossover treatment separately.

  7. Overall survival [ Time Frame: Up to 5 years ]
    Will be estimated using the Kaplan-Meier method.

  8. Progression-free survival [ Time Frame: Time from randomization to the first of these disease events: local/regional or distant breast recurrence, DCIS or invasive breast disease in contralateral breast, non-breast second primary, or death due to any cause, assessed up to 5 years ]
    Will be estimated using the Kaplan-Meier method.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PRE-REGISTRATION ELIGIBILITY
  • Post-menopausal defined as

    • Age >= 60 and amenorrhea > 12 consecutive months, OR
    • Age < 60 and amenorrhea > 12 consecutive months without another cause and documented follicle stimulating hormone (FSH) level of > 35 mIU/mL, OR
    • Previous bilateral oophorectomy
  • Histologic proof of metastatic or locally advanced, unresectable breast cancer
  • History of ER positive (+) (>= 10% of cells positive on hematoxylin and eosin stain [H&E]), HER2 negative (−) breast cancer disease, either as a

    • History of primary, operable ER+/HER2− invasive breast cancer OR
    • History of de novo metastatic breast cancer that is ER+/HER2−

      • Note: HER2− (negative) disease defined as one of the following:

        • HER2 immunohistochemistry (IHC) expression of 0, 1+ and in-situ hybridization (ISH) non-amplified
        • HER2 IHC expression of 0, 1+ and ISH not done
        • HER2 IHC expression of 2+ and ISH non-amplified
        • IHC not done and ISH non-amplified
  • Prior treatment

    • No more than two prior chemotherapy regimens in the metastatic setting
    • Prior treatment with fulvestrant in the metastatic setting is required, except for patients with a history of ER-negative metastatic breast cancer
    • Unlimited prior endocrine therapy regimens in the metastatic setting are allowed
    • No prior treatment with an aurora Kinase inhibitor (either an aurora A or pan-aurora kinase inhibitor)
  • Disease that is measurable where:

    • A non-nodal lesion is considered measurable if its longest diameter can be accurately measured as >= 2.0 cm with chest x-ray, or as >= 1.0 cm with computed tomography (CT) scan, CT component of a positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI)
    • A malignant lymph node is considered measurable if its short axis is >= 1.5 cm when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm); Note: tumor lesions in a previously irradiated area are not considered measurable disease; Note: disease that is measurable by physical examination only is not eligible
  • No history of tumors involving spinal cord or heart
  • History of brain metastases as per the following criteria:

    • Patients with a history of resected brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration
    • Patients who receive stereotactic radiosurgery or whole brain radiation for brain metastases are eligible only if they are asymptomatic and have stable MRI scans for 3 consecutive months, including < 28 days prior to pre-registration
  • Fully recovered from acute, reversible effects of prior therapy regardless of interval since last treatment;

    • EXCEPTION: neuropathies - if grade 2 neuropathies have been stable for at least 3 months since completion of prior treatment patient is eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, 2
  • Not receiving administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes
  • Willing to limit daily alcohol intake to the following: one 12-oz glass of beer, one 6-oz glass of wine, or one 1.5-oz portion of 80-proof alcohol
  • No uncontrolled intercurrent illness including, but not limited to:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Uncontrolled symptomatic cardiac arrhythmia
    • Uncontrolled hypertension (defined as blood pressure > 160/90)
  • No history of uncontrolled sleep apnea syndrome and other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease; requirement for supplemental oxygen
  • No other active second malignancy other than non-melanoma skin cancers and in situ cervical cancers within 5 years of registration

    • NOTE: A second malignancy is not considered active if all treatment for that malignancy is completed and the patient has been disease-free for at least 5 years prior to registration
  • Ability to provide written informed consent
  • Willing to return to enrolling institution for follow-up during the active treatment; event monitoring following completion of therapy may occur outside the enrolling institution
  • No history of myocardial infarction =< 6 months prior to pre-registration or New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
  • No prior allogeneic bone marrow or organ transplantation
  • No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
  • No co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
  • Able to swallow oral medication
  • No known gastrointestinal (GI) disease or GI procedures that could interfere with the oral absorption or tolerance of alisertib; examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease
  • No visceral crisis: Visceral crisis is not the mere presence of visceral metastases, but implies severe organ dysfunction as assessed by symptoms and signs, laboratory studies, and rapid progression of disease
  • No requirement for constant administration of proton pump inhibitor, H2 antagonist, or pancreatic enzymes
  • Willing to undergo a biopsy of a metastatic site of breast disease for central laboratory determination of ER and correlative research purposes
  • REGISTRATION ELIGIBILITY CRITERIA
  • =< 28 days post pre-registration
  • Central ER determination on pre-registration biopsy completed
  • Absolute neutrophil count (ANC) >= 1500/mm^3
  • Platelet count >= 100,000/mm^3
  • Hemoglobin >= 9.0 g/dL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN)
  • Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)
  • Calculated creatinine clearance must be >= 45 ml/min using the Cockcroft-Gault formula
  • Willing to provide blood and tissue for correlative research purposes

Exclusion Criteria:

  • REGISTRATION EXCLUSION CRITERIA
  • Any of the following therapies prior to registration:

    • Chemotherapy =< 21 days
    • Immunotherapy =< 21 days
    • Biologic therapy =< 21 days
    • Hormonal therapy =< 14 days
    • Monoclonal antibodies =< 14 days
    • Radiation therapy =< 14 days
  • Administration of myeloid growth factors or platelet transfusion =< 14 days prior to registration
  • Systemic infection requiring intravenous (IV) antibiotic therapy =< 14 days prior to registration
  • Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or rifampin, rifabutin, rifapentine or St. John's wort =< 14 days prior to registration
  • Receipt of corticosteroids =< 7 days prior to registration, unless patient has been taking a continuous dose of no more than 15 mg/day of prednisone for at least 30 days prior to registration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02860000


Locations
Layout table for location information
United States, District of Columbia
Georgetown University Medical Center Recruiting
Washington, District of Columbia, United States, 20007
Contact: Antonella Noviella, R.N    202-444-3932    noviella@georgetown.edu   
Principal Investigator: Claudine Isaacs, M.D.         
United States, Massachusetts
Dana-Farber Cancer Institute Recruiting
Boston, Massachusetts, United States, 02215
Contact: Research Nurse Office, R.N    617-632-3478    DFCIBOCResearchNurses@partners.org   
Principal Investigator: Eric Mayer, M.D.         
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Robert Bridges, B.A    734-936-6936    robbridg@med.umich.edu   
Principal Investigator: Aki Morikawa, M.D.         
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Clinical Trials Referral Office    855-776-0015      
Principal Investigator: Tufia C. Haddad, M.D.         
United States, New York
Montefiore Medical Center Recruiting
Bronx, New York, United States, 10461
Contact: Sun Young Oh, MD    718-405-8505      
Principal Investigator: Sun Young Oh, MD         
United States, North Carolina
Duke University Medical Center Recruiting
Durham, North Carolina, United States, 27710
Contact: Heather Sperling, MSN, RN    919-660-1278    Heather.sperling@duke.edu   
Principal Investigator: P. Kelly Marcom, MD         
United States, Pennsylvania
Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Dan Glasscott    215-615-2231    Dan.glasscott@uphs.upenn.edu   
Principal Investigator: Amy Clark, M.D.         
United States, Tennessee
Vanderbilt Breast Center at One Hundred Oaks Recruiting
Nashville, Tennessee, United States, 37204
Contact: Vanderbilt Ingram Cancer Center Eligibility Office    800-811-8480    cip@vumc.org   
Principal Investigator: Ingrid Mayer, M.D., MSCI         
Sponsors and Collaborators
Mayo Clinic
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: Tufia Haddad Mayo Clinic

Additional Information:
Layout table for additonal information
Responsible Party: Mayo Clinic
ClinicalTrials.gov Identifier: NCT02860000     History of Changes
Other Study ID Numbers: MC1431
NCI-2016-01211 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
MC1431 ( Other Identifier: Mayo Clinic )
P30CA015083 ( U.S. NIH Grant/Contract )
First Posted: August 9, 2016    Key Record Dates
Last Update Posted: April 18, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Fulvestrant
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Estrogen Receptor Antagonists
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs